• FIT Biotech Oy: Conversion of FIT Biotech Oy’s Convertible Notes into shares

    by on January 16th, 2017

    FIT Biotech Oy

    Company release January 16, 2017 at 10:00 am

    Conversion of FIT Biotech Oy’s Convertible Notes into shares

    Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the Fit Biotech Oy (“Company”) and Bracknor Investment (“Bracknor”) the Company’s board of directors has January 13, 2017 resolved to approve Bracknor’s request relating to the funding programme to convert EUR 30,000 worth of Convertible Notes into the Company’s K shares.

    Due to the conversion of the Convertible Notes, the Company issues 454,070 new K shares in the Company to Bracknor with the conversion price of EUR 0.067405 per share.

    As a result of the issue of the new K shares in the Company, the total number of shares in the Company will increase to 43,922,609 shares, and the share capital of the Company will be increased by EUR 29,999.94. After the issue of the new K shares in the Company, the Company’s shares will be divided in share series as follows: 43,852,145 K shares, 5,229 A shares and 65,235 D shares.

    The increase of the share capital and new K shares in the Company will be registered in the Trade Register on or about January 17, 2017 and the new K shares will be admitted to trading on First North Finland on or about January 18, 2017.

    FIT BIOTECH OY

    Board of Directors

    For further information:
    Chairman of the Board of Directors Juha Vapaavuori
    E-mail: juha.vapaavuori@fitbiotech.com
    Tel: +358 50 372 0824

    Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

    About FIT Biotech
    FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

    FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

    FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

    DISTRIBUTION:
    NASDAQ OMX Helsinki
    Principal media

  • Lubbock Advanced Physical Medicine Wins “Best of the West” Best Chiropractor 2017 Award from KCBD News

    by on January 15th, 2017

    LUBBOCK, Texas, Jan. 15, 2017 (GLOBE NEWSWIRE) — Dr. Korey Kothmann and the team are honored to have been awarded the “Best of the West’s” Best Chiropractor award for 2015, 2016, and now 2017. The annual awards ceremony from news channel KCBD honors providers of quality care and excellence. News Channel 11 viewers and readers are responsible for nominating and voting for those awarded this honor. Dr. Korey Kothmann, DC and the team at Lubbock Advanced Physical Medicine continue their dedication in serving the wellness and chiropractic needs of Lubbock area residents.

    Patients can find a variety of pain management and injury rehabilitation services at Lubbock Advanced Physical Medicine. Dr. Korey Kothmann is dedicated to providing drug-free care as part of individualized treatment programs for patients. The mission of the practice is to help the patient, as an individual, activate their body’s natural ability to heal itself so that the patient is able to carry out their life’s mission and purpose in abundance. Award recipients appreciate the additional attention from prospective patients when their practice or business is highlighted as an outstanding provider in the area.

    “I would highly recommend Dr. Kothmann and his professional staff for any type of chiropractic care,” said Richard Dodson, chiropractic patient in Lubbock, TX. “They know their job and they do it well. Above all, they care.”

    “We are honored by our third consecutive win of the KCBD “Best of the West” award as it testifies to our continuous efforts to meet the health and wellness needs of our patients,” said Dr. Korey Kothmann. “I appreciate that our patients and participants continue, for three years running, to share their positive experiences of the care they have received at Lubbock Advanced Physical Medicine and nominate and vote for our practice. We are grateful for the award and the support of our patients and residents of the Lubbock area.”

    Dr. Korey Kothmann of Lubbock Advanced Physical Medicine serves the chiropractic needs of residents of Lubbock and the surrounding area. This integrative pain relief rehab clinic is committed to using drug-free and non-surgical methods to bring bodies back into a state of balance and address health issues naturally. Services available at Lubbock Advanced Physical Medicine in their new location at 2230 Indiana Avenue include chiropractic care, primary care, orthopedics, physical examinations, preventative health care, gentle spinal manipulation, acute care, pediatric and senior care, physical therapy, and rehabilitation.

    Call (806) 791-3399 to speak with a knowledgeable associate about the KCBD “Best of the West 2017” award, schedule an appointment at the award-winning practice, or visit http://healthyspinelubbock.com/ for more details.

    CONTACT: Lubbock Advanced Physical Medicine, (806) 791-3399
  • Chiropractic Health Clinic Offers Natural Pain Management for Cancer Patients

    by on January 15th, 2017

    OMAHA, Neb., Jan. 15, 2017 (GLOBE NEWSWIRE) — Chiropractic is a non-invasive way to provide pain relief for cancer patients. Approximately one-to-two of every three people undergoing cancer treatment experience pain from either cancer itself or the treatment, and chiropractic adjustments have been shown to reduce side-effects associated with conventional cancer treatments. Patients can experience moderate or severe discomfort that may be constant or intermittent, mild to severe, and sharp or dull. Many cancer treatment facilities now offer chiropractic care as part of pain management programs. The Cancer Treatment Centers of America recommend cancer patients use chiropractic care as part of their program as it helps improve general health, decrease stress, and improve strength and function.  

    As cancer patients undergo treatment, they may experience significant pain, nausea, and headaches in addition to other side effects. There are a number of benefits to including chiropractic care as part of a patient’s pain management efforts. They include a decrease in the frequency of headaches and migraines, less pain and joint stiffness, and a boost to immune system response. Chiropractors rely upon spinal adjustments and other non-invasive and gentle techniques to correct musculoskeletal issues and improve nerve function.

    In an integrative care model, chiropractors share their findings with a team of experts to support the health of a cancer patient. Patients who undergo radiation treatments can develop nerve pain and muscular discomfort as they need to stay in an awkward position for an extended period. Chiropractic treatments can help alleviate discomfort and allow patients to finish a treatment session without interruption. Chiropractors are also valuable partners outside of the oncology setting and help to ensure safe and effective care through all stages of treatment and recovery. Patients with active bone cancer and with low platelet counts may not be good candidates.

    “Chiropractic care can help cancer patients manage the discomfort associated with cancer and cancer treatment,” said Dr. Mark Eiler. “As a chiropractor, I work with the support team to find ways to minimize discomfort for patients and help them throughout treatment and during recovery. Research supports the use of chiropractic for pain management and may reduce the need for opioid-based medications. Patients can address discomfort with alternative approaches to improve health and immune system response at Chiropractic Health Clinic.”

    Dr. Mark Eiler, chiropractor at Chiropractic Health Clinic, serves residents in and around Omaha. The team offers quality chiropractic care for holistic healing and spinal correction. Chiropractic is used to relief back pain, neck pain, headaches, and more at Chiropractic Health Clinic. Services include manual adjustments, nutritional counseling, lifestyle counseling, neuromuscular release, and postural and spinal screenings.

    Call (402) 778-5470 to discuss chiropractic treatment for cancer patient pain management or visit http://www.eilerchiro.com/ for more details on their hours and location.

    CONTACT: Chiropractic Health Clinic, (402) 778-5470
  • Screen opioid users for depression, study recommends

    by on January 13th, 2017

    FROM THE JOURNAL OF AFFECTIVE DISORDERS Depression combined with chronic opioid analgesic use involves more symptoms and comorbidities than depression without chronic opioid use, according to a study of Department of Veterans Affairs patients seen between 2000 and 2012. “Screening and treatment of depression in non–cancer pain patients may limit risk of persistent mood disorder […]

  • When primary anti-TNF fails in axial spondyloarthritis, consider comorbidities or second anti-TNF

    by on January 13th, 2017

    FROM RHEUMATOLOGY Most of the minority of axial spondyloarthritis patients who do not respond to their first tumor necrosis factor inhibitor still meet classification criteria for the condition 5-10 years later, but more than half respond to a second TNFi and most also have comorbidities that could affect the spondyloarthritis evaluation, according to findings from […]

  • Lower BDNF levels found in older adults with bipolar I

    by on January 13th, 2017

    FROM THE AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY Older patients with bipolar I disorder appear to have lower serum levels of brain-deprived neurotrophic factor than similarly aged adults without bipolar I, a study showed. At the beginning of the study, Aline T. Soares, MD, and her colleagues recruited 118 patients from clinics in the United States […]

  • New data signal paradigm shift in FMD and arterial disease

    by on January 13th, 2017

    AT THE NORTHWESTERN VASCULAR SYMPOSIUM CHICAGO (FRONTLINE MEDICAL NEWS) – New data have shown that fibromuscular dysplasia is associated with high rates of dissection and/or aneurysm, and emerging recommendations call for routine imaging early on in the diagnosis of FMD to monitor for these vascular events, a researcher who developed those recommendations reported at a […]

  • Aptevo Therapeutics Receives $20 Million Payment From Emergent BioSolutions

    by on January 13th, 2017

    SEATTLE, Jan. 13, 2017 (GLOBE NEWSWIRE) — Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has received a $20 million cash payment from Emergent BioSolutions pursuant to a promissory note granted as a result of the spin-off of Aptevo from Emergent, effective August 1, 2016.

    With the additional $20 million cash payment announced today, Emergent has provided a total of $65 million in cash contributions to fund Aptevo’s operations as a newly-launched oncology and hematology-focused company with a broad pipeline of commercial, clinical and preclinical assets and a proprietary bispecific technology platform, ADAPTIR™, focused on the development of immuno-oncology therapeutics.

    “The achievement of this final payment from Emergent marks another important milestone in Aptevo’s progress,” said Marvin L. White, President and Chief Executive Officer.  “With the generous funding provided by Emergent, and a strong portfolio of revenue-generating commercial assets, Aptevo is solidly positioned to achieve our near-term goals. Specifically, these include: capturing increased market share for our newly-launched Hemophilia B therapeutic, IXINITY®; generating additional data from our two clinical-stage programs, otlertuzumab and MOR209/ES414; and rapidly advancing new ADAPTIR immuno-oncology candidates into clinical development.”  

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.

    Safe Harbor Statement

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding Aptevo’s outlook, financial performance or financial condition, our technology and related pipeline, collaboration and partnership opportunities, commercial portfolio and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.

    There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on our business operations, assets or financial results as a result of the separation; a deterioration in our business or prospects; the ability of our contractors and suppliers to supply product and materials;  our ability and the ability of our contractors and suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; adverse developments in our customer-base or markets; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in our filings with the Securities and Exchange Commission, including Aptevo’s most recent Quarterly Report on Form 10-Q, as filed on November 14, 2016. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement.

    CONTACT: Source:
    
    Aptevo Therapeutics
    Stacey Jurchison
    Senior Director, Investor Relations and Corporate Communications
    206-859-6628
    JurchisonS@apvo.com
  • Aptevo Therapeutics Receives $20 Million Payment From Emergent BioSolutions

    by on January 13th, 2017

    SEATTLE, Jan. 13, 2017 (GLOBE NEWSWIRE) — Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has received a $20 million cash payment from Emergent BioSolutions pursuant to a promissory note granted as a result of the spin-off of Aptevo from Emergent, effective August 1, 2016.

    With the additional $20 million cash payment announced today, Emergent has provided a total of $65 million in cash contributions to fund Aptevo’s operations as a newly-launched oncology and hematology-focused company with a broad pipeline of commercial, clinical and preclinical assets and a proprietary bispecific technology platform, ADAPTIR™, focused on the development of immuno-oncology therapeutics.

    “The achievement of this final payment from Emergent marks another important milestone in Aptevo’s progress,” said Marvin L. White, President and Chief Executive Officer.  “With the generous funding provided by Emergent, and a strong portfolio of revenue-generating commercial assets, Aptevo is solidly positioned to achieve our near-term goals. Specifically, these include: capturing increased market share for our newly-launched Hemophilia B therapeutic, IXINITY®; generating additional data from our two clinical-stage programs, otlertuzumab and MOR209/ES414; and rapidly advancing new ADAPTIR immuno-oncology candidates into clinical development.”  

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.

    Safe Harbor Statement

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding Aptevo’s outlook, financial performance or financial condition, our technology and related pipeline, collaboration and partnership opportunities, commercial portfolio and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.

    There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on our business operations, assets or financial results as a result of the separation; a deterioration in our business or prospects; the ability of our contractors and suppliers to supply product and materials;  our ability and the ability of our contractors and suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; adverse developments in our customer-base or markets; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in our filings with the Securities and Exchange Commission, including Aptevo’s most recent Quarterly Report on Form 10-Q, as filed on November 14, 2016. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement.

    CONTACT: Source:
    
    Aptevo Therapeutics
    Stacey Jurchison
    Senior Director, Investor Relations and Corporate Communications
    206-859-6628
    JurchisonS@apvo.com
  • Oral, liquid supplement improves clinical outcomes in lactose-intolerant adults

    by on January 13th, 2017

    FROM THE PROCEEDINGS OF THE NATIONAL ACADEMIES OF SCIENCE Adults with self-reported lactose intolerance were shown to have significant improvement in their clinical outcomes, including abdominal pain, after consuming an oral, liquid supplement intended to increase lactose-fermenting gut bacteria, M. Andrea Azcarate-Peril, PhD , assistant professor of medicine at the University of North Carolina, Chapel […]

  • AGA Clinical Practice Update: CommentEndoscope reprocessing guidelines fall short on preventing outbreaks

    by on January 13th, 2017

    FROM GASTROENTEROLOGY While the 2016 Multi-Society Task Force Endoscope Reprocessing Guidelines are an improvement over the 2011 guidelines, some of its minor changes are unlikely to guarantee against prevention of future outbreaks, according to Susan Hutfless, PhD, and Anthony N. Kalloo, MD. “The prevention of future outbreaks is left to the manufacturers to modify their […]

  • Promising pipeline for chronic pruritus

    by on January 13th, 2017

    EXPERT ANALYSIS FROM THE EADV CONGRESS VIENNA (FRONTLINE MEDICAL NEWS) – Help is on the way for physicians stymied in their efforts to treat patients with severe chronic itch, Sonja Ständer, MD, declared at the annual congress of the European Academy of Dermatology and Venereology. Now working their way through the developmental pipeline are two […]

  • Rhinovirus most often caused HA-VRIs in two hospitals

    by on January 13th, 2017

    FROM JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY Health care–associated viral respiratory infections (HA-VRIs) were common in two pediatric hospitals, with rhinovirus the most frequent cause of the infections in a 3-year analysis. The incidence rate of laboratory-confirmed HA-VRIs was 1.29/1,000 patient-days in an examination of the hospitals’ patient data. Forty-eight percent of all 323 […]

Back to top